On August 1, 2025, Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million.

Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the offering. The Wilson Sonsini team included Lou Lieto, Clark Lin, Rachna Ujwal, and Esther Cynn.

For more information, please see Prime Medicine’s news release.